Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)
Jialing Lin, Sallie‐Anne Pearson, Jerry R. Greenfield, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 9, pp. 1239-1248
Open Access | Times Cited: 20

Showing 20 citing articles:

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Jonathan H. Watanabe, Jimmy Kwon, Bin Nan, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 133-138
Open Access | Times Cited: 58
Perioperative Use of GLP-1 Receptor Agonists in Patients Undergoing Cardiac Procedures: A Scoping Review
Oscar Wookey, Anna Galligan, Bruce Wilkie, et al.
Heart Lung and Circulation (2025)
Closed Access | Times Cited: 1
Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
Sibylle de Germay, Élodie Pambrun, Alexandre Pariente, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1678-1686
Open Access | Times Cited: 7
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Christopher Kanellis, Kyle Williams, Darcy Holt, et al.
The Medical Journal of Australia (2025)
Closed Access
Temporal risk patterns of severe hypovolemia associated with sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes mellitus: A self‐controlled case series study
Mitsuhiro Shikamura, Atsushi Takayama, Kasumi Yokogawa, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study
Annica Fors, Tomas Forslund, Anders Sundström, et al.
European Journal of Clinical Pharmacology (2025)
Open Access
Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
Aaron A. King, Xi Tan, Neil Dhopeshwarkar, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 5, pp. e004431-e004431
Open Access | Times Cited: 3
Use of sodium–glucose cotransporter‐2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020
M. J. Hare, W. T. Chen, Thomas Berhane, et al.
Internal Medicine Journal (2025)
Open Access
Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
Osvaldo P. Almeida
Current Opinion in Psychiatry (2025)
Closed Access
Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis
Zahid Ijaz Tarar, Umer Farooq, Ahtshamullah Chaudhry, et al.
Diagnostics (2025) Vol. 15, Iss. 6, pp. 770-770
Open Access
Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study
Jialing Lin, Tamara Y. Milder, Claire T. Deakin, et al.
Diabetes Research and Clinical Practice (2025), pp. 112242-112242
Open Access
Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights
Ahmed R. N. Ibrahim, Khalid Orayj
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6256-6256
Open Access | Times Cited: 3
Physician Perceptions of Medication Prescribing in Heart Failure: A Scoping Review
Swetha Vasudevan, Archana Thayaparan, Lung En Teng, et al.
Cardiology (2024), pp. 1-1
Closed Access | Times Cited: 2
Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes
Sahib Singh, Aakash Garg, Udaya S. Tantry, et al.
The American Journal of Cardiology (2024) Vol. 218, pp. 24-31
Closed Access | Times Cited: 1
Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
Juliana de Oliveira Costa, Jialing Lin, Tamara Y. Milder, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2787-2795
Open Access | Times Cited: 1
Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study
N Meier, Rahel Laager, Claudia Gregoriano, et al.
BMJ Open (2024) Vol. 14, Iss. 6, pp. e084526-e084526
Open Access | Times Cited: 1
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Peter Shane Hamblin, Arul Earnest, Anthony Russell, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 4924-4932
Closed Access | Times Cited: 1
New diabetic agents providing a glucose feast for urinary yeast – what to do?
Gordon Chen, Andrew A. Mahony, Janelle Brennan, et al.
BJU International (2024) Vol. 134, Iss. S2, pp. 6-8
Open Access
Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta‐Analysis
A B Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, et al.
Journal of Diabetes Research (2024) Vol. 2024, Iss. 1
Open Access
Tolerability and efficacy of sodium–glucose co‐transporter‐2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study
Noor Fishan, Kurt Towers, Javier Haurat, et al.
Internal Medicine Journal (2023) Vol. 53, Iss. 10, pp. 1916-1918
Open Access | Times Cited: 1
Page 1

Scroll to top